# Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer

> **NCT01848197** · NA · UNKNOWN · sponsor: **Taizhou Hospital** · enrollment: 1000 (estimated)

## Conditions studied

- Breast Cancer
- Paclitaxel
- Epirubicin
- Cyclophosphamide

## Interventions

- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT01848197
- **Lead sponsor:** Taizhou Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2018-12
- **Final completion:** 2020-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2013-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848197, "Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01848197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*